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impact of WLM on functioning and well-being is not well under-
stood, cultural differences have been largely ignored and discrep-
ancies between clinician and patient perceptions have been
noted. The purpose of the study was to develop a measure of the
impact of WLM applicable for use in clinical trials and clinical
practice. METHODS: Qualitative data were collected from the
literature, patients (n = 82) and experts (n = 9) in three countries
(US, France, UK) were interviewed regarding the impact of WLM
on functioning, well-being and health. Interview transcripts were
thematically coded. Based on these data, a conceptual model of
the impact of WLM on functioning, well-being and symptom
experience was developed and a patient reported outcomes
(PRO) measure generated. RESULTS: The impact of WLM on
psychological health, interference in daily life, treatment burden,
efﬁcacy and side effects was considered signiﬁcant by patients.
Key modiﬁers to this impact (i.e., age, occupation, stress) and
consequences (i.e., compliance, reduced productivity) were
noted. Based on a conceptual model, a WLM treatment related
impact measure (TRIM-Weight) was generated with ﬁve discrete
domains. Discrepancies between perceived patient and clinician
impacts were identiﬁed, most notably for the impact on sleep and
daily life as well as perceived importance of side effects. Gender
and cultural differences were also identiﬁed. For example, men
tended to be more goal-oriented in their weight loss goals than
women and side effect proﬁles differed by country as a result of
prescription patterns. CONCLUSIONS: A measure of the impact
of WLM on functioning, well-being and health was developed.
The instrument development process, full conceptual model, and
cultural, gender and clinician/patient differences will be pre-
sented. This information should help clinicians to identify key
PRO issues for WLM, facilitate targeted treatments and allow for
meaningful measurement of treatment effect.
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OBJECTIVES: To determine a Patient Acceptable Symptom State
(PASS) for European patients with moderate-severe plaque pso-
riasis, and to compare Psoriasis Activity and Severity Index
(PASI) improvement for patients attaining this state to the
current clinical trial benchmark of 75% PASI improvement from
baseline. METHODS: Patients with Psoriasis Area and Severity
Index (PASI) > 10 were randomized 1:1 to Enbrel 25 mg BIW or
Enbrel 50 mg BIW for twelve weeks as the ﬁrst stage of a
54-week trial. PASI scores can range from 0 to 72, with higher
scores indicating more severe disease and scores > 10 indicating
moderate-severe disease. Patients on the higher dose were tem-
porarily removed from treatment if their Physician Global
Assessment score determined their skin disease had become mild,
almost clear or clear. PASI was assessed at baseline and at week
12. Patients completed a satisfaction questionnaire at week 12.
Patients reporting that they were ‘very satisﬁed’ or ‘satisﬁed’
were counted as satisﬁed; all others—including those who
reported that they were ‘somewhat satisﬁed’—were counted as
not satisﬁed. The PASS method for determining a symptom state
that patients ﬁnd acceptable was developed for osteoarthritis by
Turbach, Ravaud, Baron, et al. (Annals of the Rheumatic Dis-
eases, 2005) among other authors and other diseases. Following
the Turbach et al method, a cumulative percentage of satisﬁed
patients as well as a cumulative percentage of patients who were
not satisﬁed was plotted vs. week-12 PASI. The week-12 PASI
score with the greatest separation between the two cumulative
curves was judged to be an acceptable state. The PASI improve-
ment from baseline for patients with week-12 PASI scores closest
to this state were obtained and a mean PASI improvement for
them was calculated. Patients were pooled across treatment arms
for these analyses. RESULTS: Baseline mean PASI was 22.32 for
the 711 patients. At week 12, mean PASI was 8.70, representing
a 61% PASI improvement from baseline. PASS was determined
to be a week-12 PASI of 6.9, with 66.2% of satisﬁed patients
having a week-12 PASI below (better than) 6.9 compared to
25.6% of not-satisﬁed patients. A sensitivity analysis counting
only ‘very satisﬁed’ patients as satisﬁed also determined PASS at
week 12 to be a PASI of 6.9. A week-12 PASI interval of 6.6 to
7.2 and centered on 6.9 included 32 patients, for whom the mean
PASI improvement from baseline was 62.5% with a 95% conﬁ-
dence interval of 58.2% to 66.9%. This percent improvement is
less than the 75% PASI improvement from baseline threshold
commonly used as a primary endpoint in clinical trials. CON-
CLUSIONS: These 711 moderate-severe psoriasis patients had a
Patient Acceptable Symptom State (PASS) worse than the 75%
PASI improvement commonly used as a primary endpoint in
clinical trials. Further research is needed on ways to explicitly
incorporate patient preference in estimates of clinical response.
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OBJECTIVES: To assess PRO and costs in German patients with
migraine, speciﬁcally for guideline-, non-guideline- and self-
treatment-groups. METHODS: Patients (n = 117), consecutively
recruited by physicians in general practice (n = 50) in 2005, were
categorized into the three groups (n = 65 self-treatment, n = 32
guideline-, n = 20 non-guideline-groups). PRO were assessed
by von Korff Index, SF-36, and Patient Health Questionnaire
Depression (PHQ-D) questionnaires at time of enrollment. Data
on resource utilization due to migraine was collected retrospec-
tively for 6 months. Groups were compared using multivariable
general linear modeling (GLM). RESULTS: Average duration of
migraine was about 14.1 (SD 11.8) years and was comparable
among the groups. Patients with self-treatment were younger
than patients in guideline- or non-guideline-group (40.5 vs. 47.3
vs. 45.1 years, mean age, p = 0.0224). The groups did not differ
in other socio-demographic characteristics. Mean SF-36 scores
in our study population were worse compared to the general
population in Germany (mean physical and mental component
scores 43.0  8.6, 42.0  11.9). However, groups were compa-
rable regarding SF-36, von Korff Index and PHQ-D items. Mean
total costs per patient and 6-month period were €527.50
[95%CI 251.93; 803.07] vs. €979.37 [95%CI 577.62; 1381.11]
vs. €1281.30 [95%CI 124.64; 2437.97] (self-treatment-vs.
guideline-vs. non-guideline-group, respectively, p = 0.2739, by
GLM, adjusted by age). The major cost factors in the self-
treatment group were reduction of earning capacity, remedies,
and sport activities (44.4%, 18.7%, and 15.8% of the mean
total cost per patient, respectively) while in guideline-group the
major cost factors were prescribed medications, reduction in
earning capacity, and visits to physicians (43.0%, 14.5%, and
14.3%, respectively). The major cost factors in non-guideline
and guideline-groups were similar. CONCLUSIONS: PRO in
patients with migraine are worse compared to the general refer-
ence population in Germany. Societal mean total costs and
PRO are comparable among guideline-, non-guideline- and
self-treatment-groups.
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